Advertisement
Canada markets closed
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7300
    +0.0003 (+0.04%)
     
  • CRUDE OIL

    82.72
    -0.09 (-0.11%)
     
  • Bitcoin CAD

    88,570.69
    -2,688.75 (-2.95%)
     
  • CMC Crypto 200

    1,391.55
    -32.55 (-2.29%)
     
  • GOLD FUTURES

    2,329.60
    -8.80 (-0.38%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,479.00
    -185.50 (-1.05%)
     
  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    37,899.52
    -560.56 (-1.46%)
     
  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     

Why Cronos Group Stock Fell 17% in May

Arrow descending on a graph
Arrow descending on a graph

As the cannabis industry matures, investors have gotten less patient about quarterly results. If companies don’t blow through analyst expectations, their stocks get punished.

That’s definitely the case for Cronos Group (TSX:CRON)(NASDAQ:CRON), which reported Q1 2019 results May 9 that didn’t quite hit the bar.

On the top line, revenues were $6.5 million, which was 120% higher than the $2.9 million in sales a year earlier. However, analysts were expecting $7.0 million, a $500,000 miss. On the bottom line, analysts were expecting a US$0.03 loss in the quarter; Cronos delivered a US$0.36 profit.

Don’t get too excited about the earnings beat, however. The company records the warrants issued to Altria and the Anti-Dilution Rights related to the $2.4 billion investment it made in Cronos as derivative liabilities produce gains and losses from quarter to quarter based on the fair value of those derivative liabilities. In the first quarter, that worked out to a non-cash unrealized gain of $436.4 million. If you focus on the operating loss, Cronos was able to reduce that by 75% in the quarter to $558,000.

ADVERTISEMENT

Another data point to reflect on from the quarter is the company’s cost per gram. Although it was 14% lower than a year earlier at $2.69, it’s a long way from being competitive should the wholesale and retail price of cannabis continue to decline.

While the report wasn’t terrible, the fact that the company isn’t anywhere near its 2020 target capacity of 117,000 kilograms by the end of 2020 has investors wondering if it’s unrealistic.

Another possible reason for Cronos stock being lower in May is the number of short sellers it attracts. As of the middle of the month, 15.9% of Cronos’ shares were short, the second-highest percentage for cannabis companies trading on the TSX behind only Tilray at 21.4%.

More reading

Fool contributor Will Ashworth has no position in any stocks mentioned.

 

 

The Motley Fool’s purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool Canada’s free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. Motley Fool Canada 2019